Biologics are not like small-molecule drugs. They are complex, sensitive, and alive in a way that makes stability a moving target. As a protein solution ages, it changes and those changes can mean the difference between a safe, effective therapy and one that fails in the clinic or on the shelf.
Quantifying that aging process is not a regulatory checkbox. It is one of the most critical decisions a formulation scientist makes.
Proteins Change Over Time
From the moment a protein is manufactured, it is under stress. Temperature fluctuations, pH shifts, shear forces during processing, exposure to surfaces, and simple time all drive degradation. The most common consequences include:
- Aggregation: proteins clump together, forming particles that can trigger immune responses
- Fragmentation: peptide bonds break, reducing molecular weight and activity
- Oxidation and deamidation: chemical modifications that alter structure and binding
- Conformational changes: unfolding that compromises function even before visible aggregation appears
Safety Is the Primary Driver
Protein aggregates are among the most well-documented immunogenicity triggers in biologic therapy. Regulatory agencies including the FDA and EMA have made clear that aggregation must be monitored and controlled throughout a product's lifecycle. A formulation that looks clean at release but degrades on the shelf is a patient safety issue and a liability.
Quantifying aging behavior at realistic timescales and stress conditions is how you catch these problems before they reach the clinic.
You Cannot Optimize What You Cannot Measure
Formulation development is fundamentally a comparative exercise. Does this buffer outperform that one? Does adding a surfactant reduce aggregation under freeze-thaw stress? Is the protein more stable at pH 5.5 or 6.0?
Without quantitative aging data, these questions cannot be answered with confidence. Viscosity, aggregate size distribution, hydrodynamic radius, and other measurable parameters provide the objective basis for selecting excipients, setting concentration limits, and defining storage conditions.
RheoSense viscometers enable precise viscosity measurements across formulation variables, helping teams detect early-stage changes in protein solution behavior before aggregation becomes visible or irreversible.
Regulatory Requirements Reflect Scientific Reality
ICH guidelines Q1A, Q8, and Q11 mandate stability data as a core component of any biologics submission. Real-time and accelerated stability studies, forced degradation testing, and comparability studies all depend on accurate, reproducible measurements of how the protein changes over time.
Demand for High Concentration Formulations Can Increase Complexity
The push toward subcutaneous delivery has driven protein concentrations well above 100 mg/mL in many programs. At these concentrations, viscosity and protein-protein interactions become formulation-limiting factors. A solution that behaves well at 10 mg/mL may gel, aggregate, or become uninjectable at higher concentrations, and those problems can emerge gradually over time.
Measuring viscosity as a function of aging and concentration is one of the most direct ways to predict whether a high-concentration formulation will remain viable throughout its intended shelf life.
TLDR;
Protein formulation development is not complete until you understand how your molecule ages. That understanding requires data: real measurements taken at relevant conditions, across meaningful timepoints, with instruments capable of detecting subtle changes before they become serious ones.
Quantifying protein aging is how formulation scientists protect patients, satisfy regulators, and build drugs that actually work when they are needed most.
